Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was declared a pandemic by the World Health Organization on March 11, 2020.[@bib1] This virus is responsible for a clinical condition, defined as coronavirus disease 2019 (COVID-19), with a clinical spectrum from mild respiratory and/or gastrointestinal symptoms to interstitial pneumonia with acute respiratory distress syndrome, possible multiorgan failure, and death.[@bib2] COVID-19 severity directly correlates with patient's age and presence of comorbidities.[@bib3] Proinflammatory cytokines may play an important role, especially in the more severe form of COVID-19. As a consequence, patients undergoing immunosuppressive therapy might be protected to some extent from the SARS-CoV-2 infection and its complications.[@bib4] Indeed, COVID-19 has not been described in solid organ transplant recipients so far.[@bib5] Current American Association for the Study of Liver Diseases recommendations acknowledge that post-transplant immunosuppression is not a risk factor for mortality associated with SARS-CoV-2 infection "per se," but the recommendations underline that post-transplant recipients older than 60 years are more likely to acquire SARS-CoV-2 infection. Therefore, the American Association for the Study of Liver Diseases suggests adoption of stringent prevention measures for liver transplant recipients.[@bib6]

In this article, we report the results of a survey administered to a large series of transplanted patients who were followed at the Maggiore Hospital Policlinico, Milan.

Materials and Methods {#sec1}
=====================

At the beginning of the outbreak in Italy, we recommended to all liver transplant recipients the following measures to prevent SARS-CoV-2 infection: frequent handwashing and sanitization, avoid public places and overcrowded situations, and wear a surgical mask in every public place. We later minimized in-person visits by improving the use of telemedicine.

In March, we performed a survey of our liver transplant patients to verify adherence to the preventive measures against SARS-CoV-2 and compliance with the seasonal anti-flu vaccination. We also inquired about possible symptoms or signs of COVID-19. All suspected cases were further investigated for a diagnosis.

Results {#sec2}
=======

In total, 640 patients completed the survey. The epidemiologic and clinical features of this population are reported in [Supplementary Table 1](#tblS1){ref-type="table"}. From the beginning of the pandemic in Italy as of April 4, 2020, our data show that 516 recipients (81%) adhered to at least 2 preventive measures, and 455 (71%) received the seasonal anti-flu vaccination. Thirty-four patients (5.3%) experienced a flu-like syndrome, complicated by bronchitis or bacterial pneumonia in 6; all recovered with antibiotic therapy. COVID-19 was diagnosed in 8 symptomatic recipients (overall prevalence, 1.25%), including 1 patient previously classified as having a flu-like syndrome. Epidemiologic and clinical features are reported in [Table 1](#tbl1){ref-type="table"} .Table 1Epidemiologic and Clinical Features of the Eight Liver Transplant Recipients With a Diagnosis of COVID-19\#1\#2\#3\#4\#5\#6\#7\#8Age, *y*6078655757627550SexMMMMMFMFRegionLombardyLombardyLombardyLombardyLombardyLombardyLombardyLombardyProvinceBresciaBresciaLeccoLeccoMilanoMilanBresciaMilanTime since LT, *mo*3623065187961372113ImmunosuppressionCNI + MMFCNI + MMFSteroidsCNI + MMFCNI + MMFCNI + MMFCNI + MMFCNI + steroidsSeasonal anti-flu vaccinationYesYesNoNoYesYesNoNoCardio-pulmonary comorbiditiesNo/noYes/noNo/yesYes/yesNo/noNo/yesYes/noYes/yesStart of symptomsFebruary 28March 11March 15March 15March 18March 23March 24March 25COVID-19 diagnosisNasal swab chest x-rayNasal swab chest-CT scan--- Chest-CT scanNasal swab chest x-rayNasal swab chest x-rayNasal swab chest-CT scanNasal swab chest x-rayNasal swab chest-CT scanFeverYesYesYesYesYesYesYesYesRespiratory symptomsYesYesYesYesYesYesNoYesDiarrheaNoNoNoNoNoNoYesNoPneumoniaNoYesYes (mild)NoYes (mild)Yes (mild)Yes (mild)YesHospitalizationNoYes (noninvasive ventilation)NoNoYes (discharged)Yes (discharged)Yes (discharged)Yes (noninvasive ventilation)[^1]

Discussion {#sec3}
==========

In this study we report a real-life "snapshot" of a large cohort of liver transplanted patients during the SARS-CoV-2 outbreak in Italy. Our data show an excellent adherence rate to the recommended preventive measures (84%); this high compliance with preventive strategies might have contributed to the relatively low prevalence of SARS-CoV-2 infection in our population. Nevertheless, some patients from our cohort of liver transplant recipients developed COVID-19, with an observed 1.25% infection rate so far. Noteworthy, most of the cases (75%) had a mild disease (3 quarantined and 3 rapidly discharged), whereas 2 patients are still hospitalized.

These findings slightly differ from those reported by D'Antiga[@bib7] in which some infected patients but no cases of COVID-19 were described**.** The different populations investigated by the 2 groups could explain the disparities; our cohort in Milan concerns only adult patients, whereas D'Antiga's cohort in Bergamo mainly included pediatric transplanted patients. Results may also be affected by the different time frames in the 2 reports. However, both studies showed that transplant settings may differ from the general population, possibly in regard to a high degree of surveillance at individual patient level and a milder disease expression that could be related to immune-suppressed status of liver transplant patients. Notably, all patients with COVID-19 live in Lombardy ([Supplementary Figure 1](#figS1){ref-type="fig"}), the region with the highest prevalence of infection in Italy: 10 million inhabitants with 63,094 ascertained infected people and 11,608 virus-related deaths. However, these data are not exhaustive for a correct estimation of the virus spreading in the general population because of the limited number of diagnoses performed (overall nasopharyngeal swabbing, 232,674).[@bib8]

The main merit of this preliminary study is the large sample size, with a homogeneous collection of data from a single center. The main limitations are related to the observational nature of the study and the short duration of follow-up. Overall, our study provides support for the use of telemedicine to deliver care to liver transplant recipients. Long-term clinical and epidemiologic studies in the transplant setting will be of great utility in the field.

Supplementary Material {#appsec1}
======================

Supplementary Figure 1Geographical distribution of the 8 transplanted recipients with a diagnosis of COVID-19 in Lombardy. COVID-19, corona virus disease 2019.Supplementary Table 1Demography of the 640 Liver Transplant Recipients Enrolled in the SurveyOverall, N = 640Age, *y*, median (range)63 (20--83)Age \>60 y, N (*%*)378 (59)Male, N (*%*)455 (71)Region, N (*%*) - Lombardy523 (82) - North Italy31 (5) - Central-South Italy86 (13)HCV etiology, N (*%*)241 (38)Time since LT, *mo*, median (range)98 (3--410)CNI-based immunosuppression, N (*%*)627 (98)Season anti-flu vaccination, N (*%*)455 (71)Preventive measures, N (*%*) One614 (96) Two to three516 (81)[^2]
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[^1]: CNI, calcineurin inhibitor; COVID-19, corona virus disease 2019; CT, computed tomography; LT, liver transplantation; MMF, mycophenolate.

[^2]: CNI, calcineurin inhibitor; HCV, hepatitis C virus; LT, liver transplantation.
